Ahead of World AIDS Day, Unitaid is announcing a US$22 million investment to accelerate the introduction and access to lenacapavir, a revolutionary long-acting HIV prevention option. Two injections of ...
HealthDay on MSN11h
Twice-Yearly Injection 96% Effective in Preventing HIV InfectionPeople whose partners have HIV must remember to take antiretroviral pills every single day or risk infection themselves. But ...
17h
People are at the heart of the HIV pandemic, so it’s important to understand how they make protection decisions.
Biannual vaccinations with the drug lenacapavir offers effective protection against HIV infection, according to phase-3 study ...
GlobalData on MSN18h
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trialThe Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...
For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...
For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...
Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 ...
Pre-exposure prophylaxis, post-exposure prophylaxis, and injectable treatments are all tools available and should be used ...
"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...
Lead PURPOSE researcher Moupali Das, Vice President, Clinical Development, HIV Prevention & Pediatrics, designed the PURPOSE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback